New CDE Guidelines for Cell Therapy, Chronic Heart Failure, and Oncology Biosimilars Trials

The Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has released three key guidelines, between September and November 2024, aimed at providing technical direction and fostering innovation in China’s pharmaceutical landscape.

These guidelines, effective immediately upon publication, highlight regulatory priorities in addressing unmet medical needs and advancing new therapeutic developments. This article will provide an overview of these three guidelines and examine their impact on companies focused on the Chinese pharmaceutical industry.

Overview of the New CDE Guidelines

All three guidelines aim to encourage innovation and provide technical guidance for specific areas of drug development and clinical trials, reflecting the regulatory focus on addressing unmet medical needs and fostering new therapeutic advancements.

All announcements reference compliance with the "Notice of the General Office of the National Medical Products Administration on the Procedures for the Release of Drug Technical Guidelines" (NMPA Comprehensive Drug Administration [2020] No. 9).

1. Technical Guidelines for Clinical Pharmacology Studies of Cell Therapy Products (Trial)

Purpose

This guideline is designed to provide a clear framework for conducting clinical pharmacology studies specific to cell therapy products. It focuses on ensuring the reliability and reproducibility of pharmacokinetic (PK) and pharmacodynamic (PD) data, which are critical for understanding the safety and efficacy of these advanced therapies.

Scope

This guideline applies to cell therapy products, including human stem cells, immune cell therapies, and genetically modified cells. It covers ethical sourcing, processing, and clinical trial requirements, ensuring compliance with drug management regulations for disease treatment. It does not apply to blood transfusion components, untreated hematopoietic stem cells, germline-related cells, or tissue/organ products composed of cells.

Significance

Accelerated Market Approval: By standardizing clinical pharmacology study requirements, the guideline reduces uncertainties in the regulatory review process, allowing developers to generate high-quality data more efficiently. This structured approach helps expedite the approval of cell therapy products.

Improved Safety & Efficacy: The guideline enforces rigorous testing of PK/PD parameters, ensuring that therapies demonstrate clear clinical benefits and meet strict safety standards before reaching the market. It also emphasizes ethical sourcing and controlled processing to mitigate risks associated with cell-based therapies.

Implementation

Effective from November 19, 2024, the guideline aligns with the NMPA’s 2020 procedural standards for drug technical guidelines, ensuring compliance with national regulatory expectations.

2. Technical Guidelines for Clinical Trials of Drugs for Chronic Heart Failure

Purpose

To address the critical need for effective treatments for chronic heart failure, this guideline offers comprehensive instructions for designing and conducting clinical trials in this therapeutic area. It emphasizes innovation while maintaining high safety and efficacy standards.

Scope

It is applicable to the research and development of drugs that treat chronic heart failure with chemical drugs and therapeutic biologics. Furthermore, the guideline requires reference to the International Council for Harmonization of Drugs for Human Use (ICH) and other relevant technical guidelines published in China.

Significance

Encouraging Novel Therapies: The guideline promotes the use of innovative trial designs, biomarker-driven approaches, and advanced statistical methodologies, enabling researchers to explore new treatment modalities.

Enhancing Clinical Trial Rigor: By setting clear standards for trial design, patient selection, and endpoints, it reduces variability and increases the likelihood of successful drug development. Alignment with international standards also facilitates global acceptance of trial results.

Implementation

Published on September 19, 2024, the guideline became effective immediately, enabling companies to incorporate its principles into ongoing and planned clinical studies.

3. Technical Guidelines for Clinical Trials of Biosimilar Denosumab Injection (Trial)

Purpose

This guideline focuses on the clinical development of biosimilar versions of denosumab for oncology indications. It aims to streamline the pathway for biosimilar approvals while ensuring therapeutic equivalence and safety.

Scope

This guideline is applicable to the research and development of biosimilar denosumab injections (XGEVA specification) for tumor patients, with a primary focus on preventing bone-related events in patients with multiple myeloma and bone metastases from solid tumors. It also covers clinical research for tumor indications, such as the treatment of patients with giant cell tumor of bone who are not suitable for surgery.

Significance

Faster Biosimilar Approval: The guideline establishes a standardized pathway for biosimilar clinical trials, reducing regulatory uncertainty and helping developers meet approval requirements more efficiently.

Ensuring Therapeutic Equivalence & Safety: It mandates comparative studies that demonstrate biosimilars' similarity to the reference drug in terms of efficacy, safety, and immunogenicity. This ensures that biosimilars provide the same clinical benefits as their originator biologics.

Implementation

Effective from September 19, 2024, the document provides immediate clarity for biosimilar developers, reducing uncertainties in regulatory submissions and approval processes.

Implications for Foreign Manufacturers

For medical device and pharmaceutical companies with products registered in China, these guidelines represent both opportunities and challenges. By aligning with these updated standards, companies can enhance compliance and accelerate the development of innovative therapies for the Chinese market.

Regulatory affairs and quality assurance managers should thoroughly review these documents to ensure that ongoing and future clinical trials meet the specified requirements.

Further Information

1) Read the original CDE announcement on Technical Guidelines for Clinical Pharmacology Studies of Cell Therapy Products (Trial)here.

2) Access the original CDE announcement on Technical Guidelines for Clinical Trials of Drugs for Chronic Heart Failure here

3) Read the original CDE announcement on Technical Guidelines for Clinical Trials of Biosimilar Denosumab Injection (Oncology Indications)here

GET IN TOUCH

🌐 Send us your enquiry📚 Request our whitepapers📣 Sign up for our newsletter